Pfizer Says FDA Approved Tukysa Combination for Maintenance Treatment of Metastatic Breast Cancer
MT newswire2026/10/07 17:3301:33 PM EDT, 10/07/2026 (MT Newswires) -- Pfizer (PFE) said Wednesday that the US Food and Drug Administration has approved Tukysa in combination with trastuzumab and pertuzumab for the maintenance treatment of metastatic human epidermal growth factor 2-positive breast cancer following induction treatment. The approval expands the use of Tukysa to the front-line setting, an earlier stage of metastatic disease. Tukysa is a category 1 second-line plus treatment for HER2+ metastatic breast cancer patients in the US, according to a statement. Additionally, Pfizer said the Her2climb-05 phase 3 trial showed a 35.9% reduction in the risk of disease progression or death among patients treated with Tukysa, trastuzumab and pertuzumab, compared with those treated with placebo, trastuzumab and pertuzumab, following induction treatment. Shares of the company were up 2.2% in Wednesday afternoon trading. Price: 28.11, Change: +0.61, Percent Change: +2.20
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
